I-Mab has released a corporate presentation detailing its progress and strategic initiatives in drug development. Key highlights include the advancement of their bispecific antibodies, givastomig and ragistomig, targeting gastric cancers and refractory/relapsed cancers, respectively. The presentation also outlines the ongoing Phase 1b expansion study for givastomig, which is enrolling ahead of schedule, with topline data expected in the first quarter of 2026. Additionally, I-Mab reports a strong financial position with $168.6 million in cash as of March 31, 2025, projected to support operations through 2027. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.